A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). (Q36977435)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 2007

Language	Label	Description	Also known as
English	A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).	scientific article published on November 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

5 November 2020

A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

monoclonal antibody

1 reference

27 September 2019

1 reference

based on heuristic

inferred from title

vascular endothelial growth factor A

1 reference

20 August 2020

macular degeneration

1 reference

5 November 2020

nucleotide aptamers

1 reference

14 October 2020

angiogenesis inhibitor

1 reference

5 November 2020

author name string

Manish Nagpal

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Kamal Nagpal

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

P N Nagpal

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

1 November 2007

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Indian Journal of Ophthalmology

10 references

Europe PubMed Central

PMC publication ID

17 August 2017

25 April 2019

17 September 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

20 August 2020

14 October 2020

5 November 2020

55

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

437-439

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

9 references

Europe PubMed Central

25 April 2019

Europe PubMed Central

17 September 2019

Europe PubMed Central

27 September 2019

Europe PubMed Central

20 November 2019

Europe PubMed Central

27 November 2019

Europe PubMed Central

13 December 2019

Europe PubMed Central

20 August 2020

Europe PubMed Central

14 October 2020

Europe PubMed Central

5 November 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

29 September 2017

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

29 September 2017

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

29 September 2017

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

29 September 2017

VEGF and the quest for tumour angiogenesis factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

29 September 2017

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

27 June 2018

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

4 September 2018

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

4 September 2018

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

4 September 2018

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

4 September 2018

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

4 September 2018

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635991

4 September 2018

Identifiers

10.4103/0301-4738.36478

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36977435&oldid=1517177325"